Sofinnova Partners has closed its latest flagship fund, Sofinnova Capital XI, at €650 million ($750 million) — surpassing its initial target and underscoring strong investor confidence in the firm’s healthcare-focused investment strategy.
Strong demand for healthcare expertise
The fund’s oversubscription reflects continued investor confidence in Sofinnova’s disciplined approach and track record, particularly in the challenging fundraising environment of today’s market. Capital XI has attracted support from blue-chip institutional investors, including sovereign wealth funds, leading pharmaceutical companies, insurance companies, foundations, and family offices spanning Europe, North America, Asia, and the Middle East.
The majority of investors were returning partners, but they were joined by a significant number of top-tier investors. It illustrates both the confidence of existing investors in Sofinnova’s performance, and that they can still excite fresh interest.
Antoine Papiernik, Managing Partner and Chairman of Sofinnova Partners, highlighted the significance of this achievement: “This fundraising marks a pivotal moment for Sofinnova. It gives us the firepower to double down on early-stage opportunities and reinforces our uniquely collaborative, science-driven investment approach. We’re excited to continue backing visionary entrepreneurs and advancing the next wave of breakthroughs in science and medicine to bring them to patients worldwide.”
Strategic deployment across biotech and medtech
Sofinnova Capital XI will focus on backing pioneering biopharmaceutical and medical technology companies addressing urgent unmet clinical needs. The fund is already actively deploying capital with investments made in several portfolio companies, continuing Sofinnova’s strategy of supporting early-stage ventures across Europe and North America in both initial and follow-on rounds.
The fund benefits from Sofinnova’s multi-strategy platform model and draws on the expertise of its experienced team, including Partners Maina Bhaman, Anta Gkelou, Karl Naegler, Antoine Papiernik, Henrijette Richter, and Graziano Seghezzi.
Papiernik emphasised the firm’s commitment to its collaborative approach: “Achieving this milestone in today’s volatile fundraising environment speaks to the strength of our model and the confidence our investors continue to place in us.”
Five decades of healthcare investment excellence
Founded in 1972, Sofinnova Partners brings 50 years of experience to its investment strategy, having backed over 500 companies and created market leaders globally. The firm specialises in healthcare and sustainability investments, operating as a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage.
With offices in Paris, London, and Milan, Sofinnova Partners has established itself as a deeply rooted venture capital firm in Europe. The successful close of Capital XI brings the total capital raised across Sofinnova’s platform to €1.5 billion over the past year, with the firm now managing over €4 billion in assets.
The new fund positions Sofinnova to continue its mission of supporting breakthrough innovations in healthcare, maintaining its focus on early-stage opportunities that can deliver meaningful advances in patient care while generating strong returns for its diverse investor base.
